Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity

Based on a series of basic, preclinical and clinical studies, the Poly (ADP-ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. By identifying novel predictive biomarkers of tumour cell sensitivity to olaparib...

Descripción completa

Detalles Bibliográficos
Autores principales: Frankum, Jessica, Moudry, Pavel, Brough, Rachel, Hodny, Zdenek, Ashworth, Alan, Bartek, Jiri, Lord, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484416/
https://www.ncbi.nlm.nih.gov/pubmed/25883215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484416/
https://www.ncbi.nlm.nih.gov/pubmed/25883215

Ejemplares similares